Together, our results suggest that there is crosstalk among cytokines, tumor cells, and the immune microenvironment, and they highlight the paradoxical oncogenic properties of CXCL10 in EGFR-mutant lung cancer during EGFR-TKI therapy. Here, CXCL10 is linked to lung carcinoma.